PMID- 37490021
OWN - NLM
STAT- MEDLINE
DCOM- 20230726
LR  - 20230802
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 51
IP  - 7
DP  - 2023 Jul
TI  - The anti-inflammatory and haemodynamic effects of levosimendan on advanced heart 
      failure patients: a meta-analysis of published studies.
PG  - 3000605221148402
LID - 10.1177/03000605221148402 [doi]
LID - 03000605221148402
AB  - OBJECTIVE: Increasing evidence from randomized controlled trials shows the 
      anti-inflammatory and haemodynamic effects of levosimendan in advanced heart 
      failure (AdHF), however, conflicting results have been reported in some studies. 
      The aim of this study was to estimate the anti-inflammatory and haemodynamic 
      effects of levosimendan on AdHF (registration number: INPLASY202250097). METHODS: 
      The MEDLINE, PubMed, ClinicalTrials.com and Cochrane Library databases were 
      systematically searched for studies published in English up to April 2019. Data 
      were extracted from applicable articles. Meta-analyses were performed to assess 
      interleukin (IL)-6, cardiac index, pulmonary artery pressure (PAP) and New York 
      Heart Association (NYHA) functional class efficacy outcomes, following PRISMA 
      2020 guidelines. RESULTS: A total of 11 studies were included (211 patients who 
      received levosimendan and 193 controls). Meta-analyses showed that the 
      levosimendan group displayed significantly reduced IL-6 (standardized mean 
      difference [SMD] -1.05; 95% confidence interval [CI] -1.44, -0.66; I(2 )= 50.9%), 
      improved cardiac index (SMD 0.59; 95% CI 0.29, 0.88; I(2) = 0.0%); reduced PAP 
      (SMD -1.22; 95% CI -1.91, -0.53; I(2) = 89.7%) and improved NYHA functional class 
      (SMD -1.66; 95% CI -2.27, -1.04; I(2) = 74.6%) versus controls. CONCLUSIONS: 
      Levosimendan infusion was beneficial in patients with AdHF, displayed by 
      anti-inflammatory and improved haemodynamic effects, and improved NYHA functional 
      class.
FAU - Zhou, Suzhen
AU  - Zhou S
AUID- ORCID: 0000-0002-7565-4477
AD  - Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Li, Denghua
AU  - Li D
AD  - Department of Medical Image, the Third Hospital of Nanchang, Nanchang, Jiangxi 
      Province, China.
FAU - Zhang, Lieliang
AU  - Zhang L
AD  - Department of Anaesthesiology, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
FAU - Li, Juxiang
AU  - Li J
AD  - Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 349552KRHK (Simendan)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Interleukin-6)
SB  - IM
MH  - Humans
MH  - Simendan
MH  - *Anti-Inflammatory Agents
MH  - *Heart Failure
MH  - Databases, Factual
MH  - Hemodynamics
MH  - Interleukin-6
PMC - PMC10387701
OTO - NOTNLM
OT  - Levosimendan
OT  - NYHA functional class
OT  - cardiac index
OT  - heart failure
OT  - meta-analysis
OT  - randomized controlled trial
COIS- The authors declare that there is no conflict of interest.
EDAT- 2023/07/25 13:09
MHDA- 2023/07/26 06:43
PMCR- 2023/07/25
CRDT- 2023/07/25 10:23
PHST- 2023/07/26 06:43 [medline]
PHST- 2023/07/25 13:09 [pubmed]
PHST- 2023/07/25 10:23 [entrez]
PHST- 2023/07/25 00:00 [pmc-release]
AID - 10.1177_03000605221148402 [pii]
AID - 10.1177/03000605221148402 [doi]
PST - ppublish
SO  - J Int Med Res. 2023 Jul;51(7):3000605221148402. doi: 10.1177/03000605221148402.